Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Kymera Therapeutics, Inc.KYMR · filed Jun 26, 2026

Accession no.
0000921895-26-001688
Filed
Jun 26, 2026, 6:48 PM ET
Trade date
Jun 26, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $173.7M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Director, Other: See Remarks and Footnotes
BVF Partners L PCIK 0001055947Director, Other: See Remarks and Footnotes
BVF IncCIK 0001056807Director, Other: See Remarks and Footnotes
Biotechnology Value Fund II LPCIK 0001102444Director, Other: See Remarks and Footnotes
Lampert Mark NCIK 0001233840Director, Other: See Remarks and Footnotes
Biotechnology Value Trading Fund OS LPCIK 0001660683Director, Other: See Remarks and Footnotes
BVF Partners OS Ltd.CIK 0001660684Director, Other: See Remarks and Footnotes
BVF I GP LLCCIK 0001803805Director, Other: See Remarks and Footnotes
BVF II GP LLCCIK 0001803806Director, Other: See Remarks and Footnotes
BVF GP Holdings LLCCIK 0001803809Director, Other: See Remarks and Footnotes

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 26, 2026Common Stock, $0.0001 par valueSSaleDisposed−837,914$106.50−$89,237,8411,960,881Direct
Jun 26, 2026Common Stock, $0.0001 par valueSSaleDisposed−627,597$106.50−$66,839,080.51,592,261Direct
Jun 26, 2026Common Stock, $0.0001 par valueSSaleDisposed−113,289$106.50−$12,065,278.5240,123Direct
Jun 26, 2026Common Stock, $0.0001 par valueSSaleDisposed−51,858$106.50−$5,522,87778,787Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

Read the full filing on SEC EDGAR (opens in a new tab)